Ads
related to: jak2 positive thrombocytosis treatment- Understanding CML
Patients With Ph+ CML-CP
Learn About A Treatment Option.
- Side Effects & Safety
Learn About Possible Side Effects
You May Experience During Treatment
- Side Effects On Treatment
Learn About Possible Side Effects
And Considerations With Treatment.
- CML Treatment
Visit The Patient Website To
Learn More About This Treatment.
- Understanding CML
Search results
Results From The WOW.Com Content Network
The JAK 2 gene signals a protein that promotes the growth of cells. The protein is part of a signaling pathway called the JAK/STAT pathway. The JAK2 protein controls the production of blood cells from hematopoietic stem cells which are located in the bone marrow and can eventually become platelets, red blood cells or white blood cells.
In cases of reactive thrombocytosis of more than 1,000x10 9 /L, it may be considered to administer daily low dose aspirin (such as 65 mg) to minimize the risk of stroke or thrombosis. [ 11 ] However, in essential thrombocythemia where platelet counts are over 750x10 9 /L or 1,000x10 9 /L, especially if there are other risk factors for ...
Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase.It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g., IL-6R), and the single chain receptors (e.g. Epo-R, Tpo-R, GH-R, PRL-R).
A mutation in the JAK2 kinase (V617F) is strongly associated with polycythemia vera. [18] [19] While it is a JAK2 V617F mutation in 95% of patients, JAK2 exon 12 mutations have also been observed. [20] The V617F mutation is not inherited, but develops as a somatic mutation in the erythroid progenitor cells. [21]
Lestaurtinib has undergone clinical trials for the treatment of various cancers, including pancreatic and prostate cancers, V617F JAK2 positive polycythemia vera and essential thrombocytosis, [1] and refractory neuroblastoma. [5] The most significant effort was invested in developing lestaurtinib for the treatment of acute myelogenous leukemia ...
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. [2]
Ads
related to: jak2 positive thrombocytosis treatment